Advertisement

Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly

Published:October 12, 2022DOI:https://doi.org/10.1016/j.clgc.2022.10.002

      Highlights

      • The explosion of therapeutic opportunities for patients with urothelial carcinoma raised concerns regarding the impact of geographical location on access to care, management decisions, outcomes.
      • Nowadays, addressing disparities in timely access to novel therapies is a primary goal of patients’ care.

      Abstract

      After several decades of therapeutic stagnation, the treatment of patients with urothelial carcinoma has met a revolutionary wave, anticipated by the advent of immune-checkpoint inhibitors (ICI) and followed by newer therapeutic options in the post-ICI setting.
      These achievements were made in a very short time-frame, thus making the treatment of this disease particularly susceptible to geographical health disparity due to the differences in healthcare systems and approval processes of the regulatory authorities.
      Furthermore, additional barriers to access innovative care are represented by a limited coverage of clinical trials availability, that is consistent in focusing on selected geographical areas, across trials and clinical settings. Here, we present the current picture of new drug approvals in urothelial carcinoma worldwide, and we also focus our considerations onto the spectrum of ongoing trial inclusion possibilities, trying to understand what are the current gaps in clinical research and routine practice, identifying a way to move forward.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rouprêt M
        • Babjuk M
        • Comperat E
        • et al.
        European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update.
        Eur Urol. 2018; 73: 111-122
        • Siegel RL
        • Miller KD
        • Jemal A.
        Cancer statistics, 2019.
        CA Cancer J Clin. 2019; 69: 7-34
        • Munoz JJ
        • Ellison LM.
        Upper tract urothelial neoplasms: incidence and survival during the last 2 decades.
        J Urol. 2000; 164: 1523-1525
        • Powles T
        • Bellmunt J
        • Comperat E
        • et al.
        Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.
        Ann Oncol. 2022; 33: 244-258
        • Flaig TW
        • Spiess PE
        • Agarwal N
        • et al.
        Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
        J Natl Compr Canc Netw. 2020; 18: 329-354
        • Joshi M
        • Polimera H
        • Krupski T
        • Necchi A.
        Geography Should Not Be an "Oncologic Destiny" for Urothelial Cancer: Improving Access to Care by Removing Local, Regional, and International Barriers.
        Am Soc Clin Oncol Educ Book. 2022; 42: 1-4
        • Balar AV
        • Castellano D
        • O'Donnell PH
        • et al.
        First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
        Lancet Oncol. 2017; 18: 1483-1492
        • Balar AV
        • Galsky MD
        • Rosenberg JE
        • et al.
        Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
        Lancet. 2017; 389: 67-76
        • Martini A
        • Raggi D
        • Fallara G
        • et al.
        Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: a systematic review and meta-analysis.
        Cancer Treat Rev. 2022; 104102360
        • Uyl-de Groot CA
        • Heine R
        • Krol M
        • Verweij J.
        Unequal access to newly registered cancer drugs leads to potential loss of life-years in Europe.
        Cancers. 2020; 12: 2313
        • Powles T
        • Park SH
        • Voog E
        • et al.
        Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
        N Engl J Med. 2020; 383: 1218-1230
        • Bellmunt J
        • de Wit R
        • Vaughn DJ
        • et al.
        Pembrolizumab as second-line therapy for advanced urothelial carcinoma.
        N Engl J Med. 2017; 376: 1015-1026
        • Rosenberg JE
        • O'Donnell PH
        • Balar AV
        • et al.
        Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy.
        J Clin Oncol. 2019; 37: 2592-2600
        • Powles T
        • Rosenberg JE
        • Sonpavde GP
        • et al.
        Enfortumab vedotin in previously treated advanced urothelial carcinoma.
        N Engl J Med. 2021; 384: 1125-1135
        • Van der Heijden MS
        • Gupta S
        • Galsky MD
        • et al.
        Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress).
        J Clin Oncol. 2022; 40
        • Tagawa ST
        • Balar AV
        • Petrylak DP
        • et al.
        TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors.
        J Clin Oncol. 2021; 39: 2474-2485
        • Grivas P
        • Tagawa ST
        • Bellmunt J
        • et al.
        TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy.
        J Clin Oncol. 2021; 39
        • Loriot Y
        • Necchi A
        • Hoon Park S
        • et al.
        Erdafitinib in locally advanced or metastatic urothelial carcinoma.
        N Engl J Med. 2019; 381: 338-348
        • Siefker-Radtke AO
        • Necchi A
        • Park SH
        • et al.
        Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
        Lancet Oncol. 2022; 23: 248-258
        • Loriot Y
        • Maroto Rey JP
        • Necchi A
        • et al.
        Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients with metastatic or surgically unresectable urothelial carcinoma and selected FGFR gene alterations - the phase 3 THOR study. 3rd Global Congress on Bladder Cancer (BLADDR), Madrid, Spain2018 (20-21 September)
        • Bajorin DF
        • Witjes JA
        • Gschwend JE
        • et al.
        Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma.
        N Engl J Med. 2021; 384: 2102-2114
        • Necchi A
        • Galsky MD
        • Shore ND
        • et al.
        Perioperative pembrolizumab or pembrolizumab + enfortumab vedotin and cystectomy versus cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer: Phase 3 KEYNOTE-905/EV-303 study. 13th European Multidisciplinary Congress on Urological Cancers (EMUC), Athens, Greece2021 (Poster Session (P141)25-28 November)
        • Sonpavde G
        • Necchi A
        • Gupta S
        • et al.
        A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC).
        J Clin Oncol. 2020; 38
        • Hoimes CJ
        • Bedke J
        • Loriot Y
        • et al.
        KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).
        J Clin Oncol. 2021; 39
        • Powles T
        • Meeks JJ
        • Galsky MD
        • et al.
        A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA).
        J Clin Oncol. 2021; 39
        • Siefker-Radtke AO
        • Steinberg GD
        • Bedke J
        • et al.
        Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866.
        J Clin Oncol. 2020; 38
        • Balar AV
        • Kamat AM
        • Kulkarni GS
        • et al.
        Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
        Lancet Oncol. 2021; 22: 919-930
        • Shariat SF
        • Steinberg G
        • Kamat AM
        • et al.
        718TiP - KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guérin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC).
        Ann Oncol. 2021; 32: S678-S724
        • Van der Heijden MS
        • Cutie C
        • Hampras S
        • et al.
        SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin who are ineligible for or decline radical cystectomy.
        J Clin Oncol. 2022; 40
        • Shore ND
        • Powles T
        • Bedke J
        • et al.
        A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin unresponsive high-risk non-muscle invasive bladder cancer: CREST study cohort B.
        J Clin Oncol. 2022; 40
        • Hoimes CJ
        • Flaig TW
        • Milowsky MI
        • et al.
        Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer.
        J Clin Oncol. 2022; JCO2201643https://doi.org/10.1200/JCO.22.01643
        • Rosenberg JE
        • Park SH
        • Kozlov V
        • et al.
        Durvalumab plus olaparib in previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma: a multicenter, randomized, phase II trial (BAYOU).
        J Clin Oncol. 2022; JCO2200205https://doi.org/10.1200/JCO.22.00205
        • Grivas P
        • Pouessel D
        • Park CH
        • et al.
        TROPHY-U-01 Cohort 3: sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.
        J Clin Oncol. 2022; 40
        • Galsky MD
        • Del Conte G
        • Foti S
        • et al.
        Primary analysis from DS8201-A-U105: A phase 1b, 2-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
        J Clin Oncol. 2022; 40
        • Oyer RA
        • Hurley P
        • Boehmer L
        • et al.
        Increasing racial and ethnic diversity in cancer clinical trials: an American society of clinical oncology and association of community cancer centers joint research statement.
        J Clin Oncol. 2022; 40: 2163-2171
        • Emanuel EJ
        • Wendler D
        • Grady C.
        What makes clinical research ethical?.
        JAMA. 2000; 283: 2701-2711